VIVA BIOTECH (01873) rose more than 13%, reaching HK$2.2 by the time of writing, with a turnover of HK$4.82 million. The surge follows news on December 13 that Swedish Orphan Biovitrum AB (Sobi), a global biopharmaceutical company, has entered into an acquisition agreement with Arthrosi, a firm in which VIVA BIOTECH participated in investment and incubation.

Under the terms of the deal, Sobi will pay up to $1.5 billion in total consideration, including $950 million upfront (subject to customary adjustments) and up to $550 million in regulatory and commercial milestone payments. The transaction is expected to close in the first half of 2026.

VIVA BIOTECH anticipates receiving a maximum return of approximately $40 million from this transaction, contingent upon the achievement of regulatory approvals and commercialization milestones. Additionally, Arthrosi has signed a new Statement of Work (SOW) with VIVA BIOTECH's CDMO subsidiary, Langhua Pharmaceutical, for active pharmaceutical ingredient supply, ensuring continued business collaboration between the two companies.